Acute fulminant liver failure due to COVID -19: A Case Report

Abstract

The SARS-CoV-2 virus, a novel coronavirus that first caused a series of pneumonia cases in Wuhan, China at the end of 2019, has caused Coronavirus Infectious Disease-19 (COVID-19) ranging in severity from mild asymptomatic disease to severe acute respiratory distress syndrome and has become a central health problem world wide for one year . We aimed to share our case who developed liver failure due to covid-19, which is more severe than we have encountered in the only literature published so far.Our case is a 67-year-old medical doctor with advanced heart failure, chronic renal failure,hypertension and diabetes. When we excluded other causes, the patient died of fulminant liver failure, which we think was due to covid -19.Although our knowledge about SARS-CoV-2 is not sufficient yet, we think that it should be kept in mind that it may also cause fulminant liver failure.

Keywords

• fulminant liver failure
• acute hepatitis
• covid-19

References

1. 1) Cheung KS, Hung IFN, Chan PPY et al (2020) Gastrointestinal manifestations of SARS-CoV2 infection and virus load in fecal samples from a Hong Kong cohort: Systematic review and meta-analysis. Gastroenterology 159(1): 81–95
2. 2) Melquist, S., Estepp, K., Aleksandrovich, Y., Lee, A., Beiseker, A., Hamedani, F. S., Bassett, J (2020) COVID-19 presenting as fulminant hepatic failure: A case report. Medicine 99(43).
3. 3) Wander P, Epstein M, Bernstein D (2020) COVID-19 presenting as acute hepatitis. Am J Gastroenterol 115(6): 941–42
4. 4) Zhang C, Shi L, Wang FS (2020) : Liver injury in COVID-19: Management and challenges. Lancet Gastroenterol Hepatol 5(5): 428–30
5. 5) Lee YH, Bae SC, Song GG(2013) Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. Int J Rheum Dis 16(5): 527–31
6. 6) Ong J, Young BE, Ong S (2020) COVID-19 in gastroenterology: a clinical perspective. Gut 69:1144–5.
7. 7) Shiraki K, Daikoku T (2020) Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacology & Therapeutics 10751.